EUVIMEDEUVIMED entdecken
Übersichtsarbeit

HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls

Huina Zhang iD, Brian S Finkelman, Mark G Ettel, Moises J Velez, Bradley M Turner, David G Hicks

Histopathology · 2024-07 · 85 (1) · 3-19

DOI: 10.1111/his.15170 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Histopathology, online erschienen am 05.03.2024. Verfasst von Huina Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Biomarkers, Tumor, Clinical Decision-Making. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 118 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The significant clinical benefits of human epidermal growth factor receptor 2 (HER2)‐targeted therapeutic agents have revolutionized the clinical treatment landscape in a variety of human solid tumours. Accordingly, accurate evaluation of HER2 status in these different tumour types is critical for clinical decision making to select appropriate patients who may benefit from life‐saving HER2‐targeted therapies. HER2 biomarker scoring criteria is different in different organ systems, and close adherence to the corresponding HER2 biomarker testing guidelines and their updates, if available, is essential for accurate evaluation. In addition, knowing the unusual patterns of HER2 expression is also important to avoid inaccurate evaluation. In this review, we discuss the key considerations when evaluating HER2 status in solid tumours for clinical decision making, including tissue handling and preparation for HER2 biomarker testing, as well as pathologist's readout of HER2 testing results in breast carcinomas, gastroesophageal adenocarcinomas, colorectal adenocarcinomas, gynaecologic carcinomas, and non‐small cell lung carcinomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorClinical Decision-MakingHumansNeoplasmsBreast NeoplasmsFemaleImmunohistochemistry

Stichwörter der Autor:innen

HER2breast cancercolorectal adenocarcinomagastroesophageal adenocarcinomagynaecologic carcinomanon‐small cell lung carcinoma

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA.

ORCID-Profile: Huina Zhang

Zitieren

APA

Zhang, H., Finkelman, B. S., Ettel, M. G., Velez, M. J., Turner, B. M., & Hicks, D. G. (2024). HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls. Histopathology, 85(1), 3-19. https://doi.org/10.1111/his.15170

Vancouver

Zhang H, Finkelman BS, Ettel MG, Velez MJ, Turner BM, Hicks DG. HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls. Histopathology. 2024;85(1):3-19. doi:10.1111/his.15170

BibTeX
@article{Zhang2024,
  author = {Zhang, Huina and Finkelman, Brian S and Ettel, Mark G and Velez, Moises J and Turner, Bradley M and Hicks, David G},
  title = {HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls},
  journal = {Histopathology},
  year = {2024},
  volume = {85},
  number = {1},
  pages = {3--19},
  doi = {10.1111/his.15170}
}
Kostenlos starten →